Joint-pain comorbidity, health status, and medication use in hip and knee osteoarthritis: A cross-sectional study
Article first published online: 28 DEC 2011
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 1, pages 54–58, January 2012
How to Cite
Hoogeboom, T. J., den Broeder, A. A., Swierstra, B. A., de Bie, R. A. and van den Ende, C. H. M. (2012), Joint-pain comorbidity, health status, and medication use in hip and knee osteoarthritis: A cross-sectional study. Arthritis Care Res, 64: 54–58. doi: 10.1002/acr.20647
- Issue published online: 28 DEC 2011
- Article first published online: 28 DEC 2011
- Accepted manuscript online: 27 SEP 2011 10:31AM EST
- Manuscript Accepted: 13 SEP 2011
- Manuscript Received: 30 JUN 2011
- Sint Maartenskliniek
To determine the prevalence of joint-pain comorbidities in individuals with hip or knee osteoarthritis (OA) and to assess the differences in the characteristics of people with and without joint-pain comorbidities.
In this cross-sectional study, individuals referred to secondary care for treatment of hip/knee OA completed questionnaires to determine sociodemographic characteristics, disease-related outcomes, and joint-pain comorbidities. Joint-pain comorbidity was defined as pain perceived in a joint, other than the index joint, for more than half of the days in the preceding month. To compare differences in patient- and disease-related characteristics between participants with and without joint-pain comorbidities, we performed analyses of covariance and logistic regression.
A total of 401 individuals, 117 with hip OA and 284 with knee OA, returned the questionnaire (82% response rate); the mean ± SD age was 58 ± 13 years and 58% of the responders were women. Fifty-eight percent of the participants reported symptoms in ≥1 other joint. Participants with joint-pain comorbidities were more likely to be women, less educated, and have more medical comorbidities. Individuals with joint-pain comorbidities reported unfavorable outcomes on pain, functioning, fatigue, distress, and health-related quality of life compared with patients without joint-pain comorbidities (P < 0.001 for all). Moreover, use of nonsteroidal antiinflammatory drugs (P = 0.038), opioids (P = 0.010), and supplements (P = 0.019) was higher in the group with joint-pain comorbidities.
Our results indicate that individuals with joint-pain comorbidities represent a clinically relevant and large subgroup of people with OA of the knee or hip. We recommend addressing joint-pain comorbidities in both research and clinical practice.